Please note:This study is now full and is not recruiting at this time. When the study re-opens, we will announce its resumption on this page.
The Survivorship Program at Dana-Farber is conducting a research study to look at the effectiveness of a group-based weight loss program to help cancer survivors lose weight and feel better after completing cancer treatment.
Many patients gain weight as a result of their cancer therapy. In addition to the distress this can cause, some studies have suggested that excess weight can lead to increased side effects from treatment, such as fatigue.
In addition, studies suggest that patients who lose weight through diet and exercise may have more energy, feel better, and be at lower risk of developing other medical problems such as high blood pressure or diabetes. However, few programs have been designed to help cancer survivors lose weight or prevent additional weight gain in the years after cancer.
The Healthy Living study is being done to see if a diet and exercise program will lead to weight loss in cancer survivors. The study will also aim to find out if the program leads to increases in muscle mass and decreases in body fat, increased fitness, better quality of life, less fatigue, and changes in diet and exercise patterns.
This study has been approved by the Institutional Review Board (IRB) of Dana-Farber Cancer Institute. All individual data will be kept confidential. Group data may be presented or published, but no identifying data would be included.
If you decide to join, you will be randomly assigned to immediate participation in the weight loss program, or to delayed participation after a 15-week waiting period. The program will involve weekly meetings for 15 weeks. Each session will last 60 minutes and will consist of discussion of a diet and/or exercise topic. You will receive a Fitbit to use during the 15 weeks and a weight loss cookbook. You may withdraw from the study at any time.
The classes will be led by a dietitian and an exercise specialist with expertise in working with cancer patients. Principal Investigator for the study is Jennifer Ligibel, MD.
If you have questions or would like to discuss study participation, please call Keelin O'Connor at 617-632-5584.
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: